Imagine you are a pilot flying at thirty thousand feet. The cloud layer is so thick, you cannot see more than 40 feet ahead of you. In addition, your gauges and computers are down. Other than a few cloud breaks now and then, you are flying blind.
You have just experienced what it is like to manage type 2 diabetes with only blood glucose (BG) readings. In my experience as a physician, when a patient visits me, they share their logbook with one, two, maybe three fingerstick data points representing a whole day. With this data and an A1C number, I’m supposed to make therapy decisions.
Under those conditions, the control tower might applaud the pilot getting from point A to point B and didn’t crash, but how many times did the pilot veer out of their flight path or come close to danger? With professional continuous glucose monitoring (CGM), physicians can quickly uncover important data needed to make therapy decisions, reveal glycemic variability, and identify previously missed glucose trends, leading to improved glucose control.[i] This data can translate into more personalized insights – and therefore better – therapy decisions for my patients.
BG testing and A1C alone are not optimal; they only provide isolated points in time. Despite the most diligent adherence to therapy, about 50% of people with type 2 diabetes are not in good glucose control.[ii] Easily measuring, interpreting, and reporting the impact of BG levels and how it changes – not one finger prick at a time, but over a defined period of time – could help drive better outcomes in the 50% of patients who are not in control. In fact, using professional CGM, eight out of ten people with diabetes saw better glucose control and felt more engaged with their physician.[i]
Recently, new study results presented at the 9th international Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2016) provide additional evidence. A retrospective analysis using CGM data from 70,000 people with type 2 diabetes demonstrated that these patients experience high rates of glycemic variability, hypoglycemia, and hyperglycemia, regardless of whether they manage their diabetes with diet/exercise, oral medication, or insulin.[iii] In another study, physicians were able to successfully improve A1C in patients with poorly-controlled type 2 diabetes on a wide variety of treatments, including those on lifestyle therapy or oral medication. This suggests using iPro2 Professional CGM provides physicians with actionable insights to help them successfully optimize therapy.
While professional CGM can provide valuable insights and actionable information about glycemic variability, the data can be overwhelming. Three days of readings can equal over 800 data points! Just imagine if physicians could quickly organize this patient data into meaningful insights.
This is where CareLink iPro Pattern Snapshot comes in. Designed to help physicians efficiently review patients’ CGM data, quickly uncover the most important metrics[iv], and educate and coach patients, CareLink iPro Pattern Snapshot is a single-page report that analyzes the CGM data, prioritizing the top three glycemic issues. It then identifies up to six reasons that may explain each of these areas of concern, such as skipped snack or insulin taken at the wrong time.
Professional CGM removes ‘flying blind’ situations and gives an unobstructed view into what’s really happening. Being able to clearly define and show patients the link between their lifestyle and glucose trends provides a valuable educational tool that can help mitigate health and financial burdens associated with diabetes complications, delivering better clinical and economic outcomes.
IMPORTANT SAFETY INFORMATION
Medtronic Diabetes Continuous Glucose Monitoring (CGM) Systems
– The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a home glucose meter. A confirmatory fingerstick is required prior to treatment.
– Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
CareLink Therapy Management Software
CareLink® Therapy Management Software for Diabetes is intended to be used together with advice from a healthcare professional familiar with the diagnosis and treatment of diabetes. Do not make any changes to treatment without talking to a healthcare professional first.
For more information, please visit http://www.medtronicdiabetes.com/important-safety-information.
[i] Mohan, V. Jain, S. Kesavadev, J. Chawla, M, et al. (2016) Use of Retrospective Continuous Glucose Monitoring for Optimizing Management of Type 2 Diabetes in India. Journal of The Association of Physicians of India, 64.
[ii] García-Pérez, L., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013). Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Therapy, 4(2), 175-194. doi:10.1007/s13300-013-0034-y
[iii] McMahon, C. (2016) Glycometrics in 70,167 Patients with Type 2 Diabetes Derived from Retrospective Continuous Glucose Monitoring (CGM). Abstract ATTD-0348.
[iv] Based on market research, qualitative interviews with primary care physicians and endocrinologists, April 2015
, blood glucose
, continuous glucose monitor
, professional CGM
, type 2 diabetes